A recent Interesting Engineering article discussed a new pill from Pfizer that’s intended to treat COVID-19. A press release from the company says the oral medication can reduce a patient’s risk of hospitalization or death by a whopping 89% when taken within the first five days of symptoms. The pill, called Paxlovid, is similar to one from Merck that received U.K. approval last week. Now, Pfizer is seeking emergency use authorization for its oral antiviral candidate with data claiming it “has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations.”
Pfizer’s Antiviral COVID-19 Pill Lowers Risks 89%
A tiered pricing approach will help establish equitable access across the globe to hopefully put an end to the pandemic.
Nov 16, 2021
Recommended
Recommended
Break out of the ordinary: see what’s new in life sciences packaging
At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.
REGISTER NOW & SAVE!
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
